hVIVO #HVO – Influenza HCT contract signed with Traws Pharma & launch of unified brand identity April 14, 2026 – Posted in: Blog, hVIVO (HVO)

London, UK – 14 April 2026 hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that it has signed a Clinical Trial Agreement (“CTA”) to conduct a human challenge (HCT) trial on behalf of Traws Pharma (NASDAQ: TRAW), a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases. The trial will test Traws’ prophylactic antiviral candidate, tivoxavir marboxil (“TXM”), using the hVIVO Influenza Human Challenge…

#HVO hVIVO – POSITIVE RESULTS FROM CLIENT PHASE 2B FIELD STUDY June 30, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO recruited participants and performed the virology and immunology laboratory services for the study hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, congratulates Cidara Therapeutics (Cidara: Nasdaq CDTX) on the positive topline results from their Phase 2bfield study, for which hVIVO recruited participants and performed the virology and immunology laboratory services. The study was to determine the efficacy of Cidara’s drug-Fc conjugate, CD388, which is…

Open Orphan #ORPH – £7.2m RSV human challenge study contract June 14, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £7.2m contract with an existing top 5 global pharmaceutical company to test its orally administered antiviral product, using hVIVO’s respiratory syncytial virus (“RSV”) Human Challenge Study Model. The Phase 2a double-blinded placebo-controlled human challenge study will take…

Open Orphan #ORPH – £7.3m Influenza human challenge study contract win May 18, 2022 – Posted in: Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £7.3m influenza human challenge study (“Study”) contract with a leading biotechnology company to test its antiviral product using the hVIVO Influenza Human Challenge Study Model. The randomised, double-blinded, placebo-controlled study will test and assess the antiviral prophylactic and…

Open Orphan #ORPH – COVID-19 Characterisation Study peer reviewed results published in industry leading periodical Nature Medicine March 31, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that the results from the world’s first COVID-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. ‘Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge’ by Killingley, B. et al. is available in Nature Medicine, https://www.nature.com/articles/s41591-022-01780-9 DOI: 10.1038/s41591-022-01780-9 The study, which was…

Open Orphan #ORPH – Results from the world’s first COVID-19 Characterisation Study February 2, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the results from the world’s first COVID-19 characterisation study, which was a partnership between hVIVO, Imperial College London, the Vaccine Taskforce and Department of Health and Social Care (DHSC), and the Royal Free London NHS Foundation Trust. The results from this landmark study, show that a SARS-CoV-2…

New York Times – Would You Let a Scientist Infect You With COVID? October 14, 2021 – Posted in: Blog, Open Orphan (ORPH)

By Kate Murphy, New York Times In an age of masking, compulsive hand sanitizing and plexiglass dividers, it seems inconceivable that for more than 40 years people enthusiastically signed up — and were often put on a waiting list — to have respiratory viruses, including coronaviruses, dripped into their noses. They were volunteers at the Common Cold Unit, set up in 1946 by the British government’s Medical Research Council… …aim of the study was to…

WSJ – Researchers Ready Lab-Grown Covid-19 Delta Variant for Human Trials August 27, 2021 – Posted in: Blog, Open Orphan (ORPH)

U.K. company is growing the highly contagious variant under tight lab controls for use in challenge studies Scientists have coaxed the Delta strain to mature, said Andrew Catchpole, chief scientiic oficer of trial partner hVivo. PHOTO: HVIVO SERVICES LIMITED by Jenny Strasburg – Wall Street Journal LONDON—While the rest of the world is trying to stamp out the Covid-19 Delta variant, British researchers are making progress growing a carefully controlled batch in a lab that…

Open Orphan #ORPH – World’s first Covid-19 human challenge study to expand July 14, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, is continuing to work with the UK Government to inoculate up to 20 further volunteers as part of the world’s first COVID-19 characterisation study. As part of the characterisation study, researchers aimed to identify a dose of COVID-19 that…

Open Orphan #ORPH – £3m COVID-19 challenge virus manufacturing contract for hVIVO based on new COVID-19 variants May 9, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan plc, has signed a contract with Imperial College London, as part of a Wellcome Trust funded initiative to manufacture a SARS-CoV-2 challenge virus. The contract is worth £3 million and under this agreement hVIVO will develop a new SARS-CoV-2…